Every cancer specimen is genetically unique, yet all share common traits like uncontrolled division and co-opting normal cell survival mechanisms. The key to treatment is finding pathways that are different enough from normal cells to target and exploit.

Relying on a single safety mechanism is risky for potent therapies. A more robust approach stacks multiple independent layers of control: localized administration, requiring a separate prodrug for activation, and exploiting the inherent vulnerability of rapidly dividing cancer cells.

The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

Similar to aging, cancer is a state where cells lose their original identity. By applying age-reversal technologies, cancer cells can be forced to become normal again or even self-destruct, offering a novel approach to cancer treatment.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

Cancer cells down-regulate microRNAs to enable growth. This biological shift creates an opening for Nuago's therapy to access the cell's machinery. Healthy cells, with high microRNA expression, naturally block the therapy. This provides inherent selectivity, a huge therapeutic window, and minimal toxicity by design of fundamental biology.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

The characteristic that makes stem cells invaluable—their ability to self-renew for a lifetime—is the same immortalization program that cancer cells hijack to grow without constraint. This highlights cancer's parasitic relationship with a fundamental biological process needed for survival.

For solid tumors, the critical design hurdle for T-cell engagers is achieving selectivity. Most target antigens are also expressed at low levels on healthy cells, so molecules must be engineered to attack tumors with high antigen expression while sparing healthy tissue to avoid on-target, off-tumor toxicity.